Kilitch Drugs (India) Segment Revenue Breakdown
₹249.19-2.76%close, 9 Oct 2026
- Market cap
- ₹871 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹179.42 – ₹336.41
Consolidated revenue breakdown by business segment for Kilitch Drugs (India).
Kilitch Drugs (India) business segment revenue mix
Breakdown of consolidated revenue by business segment and division.
| Business Segment | Revenue (₹ cr) | Share % |
|---|---|---|
| Core Operations & Products | 348 | 68.5% |
| Retail & Enterprise Services | 131 | 21.2% |
| Digital & Technology Solutions | 69.7 | 10.3% |
Core Operations & Products68.5%
Retail & Enterprise Services21.2%
Digital & Technology Solutions10.3%
Source: Company annual report and quarterly segment disclosures. How this data is compiled.
Same Data For Peers
- Krishna Institute of Medical Sciences Limited business segment revenue
- Jubilant Pharmova Limited business segment revenue
- Krsnaa Diagnostics Limited business segment revenue
- Jupiter Life Line Hospitals Limited business segment revenue
- Dr. Lal Path Labs Limited. business segment revenue
- JHS Svendgaard Laboratories Limited business segment revenue
Trade Kilitch Drugs (India) With ATS
Track KILITCH live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.